Abstract

Background: The prevalence of atopic disease, which consists of conditions such as atopic dermatitis, allergies, and asthma, has been on the rise in recent decades. In children, atopic dermatitis often acts as an initial manifestation of atopic disease and frequently precedes the development of food allergies, asthma, and allergic rhinitis. Mutations in the FLG gene, encoding the fillagrin precursor profillagrin, serve as a genetic risk factor for these diseases. Approximately 25%–50% of individuals with atopic dermatitis carry FLG mutations. It has been proposed that FLG mutations exhibit variations specific to different populations, indicating distinct patterns within each population.
Severe allergic symptoms could indicate the presence of an underlying immunodeficiency or immune dysregulation and in patients with severe, early-onset, or simultaneous allergic conditions, these could be suggestive of an underlying Primary Atopic Disorder. Specifically, the allergic triad characterized by elevated IgE levels, eosinophilia, and eczema is a common feature in various inborn errors of immunity that could be mistakenly diagnosed as severe allergic conditions.
Method: Our patient’s medical record was analyzed retrospectively, including her medical history, as well as results from immune laboratory tests and genetic analyses.
Results: We present a 9-year-old female of mixed ethnicity with a history severe eczematous rash diagnosed with atopic dermatitis. Whole exome sequencing analysis revealed an initially novel heterozygous variant in the FLG gene (NM_002016: EXON3:c.C2218T: p.R740X).
Conclusion: Healthcare providers caring for patients with atopic dermatitis and recurrent staphlococcus infections should be aware of the significant link between filaggrin gene mutations and the development of severe, persistent atopic dermatitis that begins in childhood, as well as its association with recurring staphlococcus infections. Additionally, they should keep in mind that certain inborn errors of immunity may predominantly manifest as severe and treatment-resistant atopic disorders.
Statement of novelty: We have identified a rare variant in the FLG gene associated with severe atopic dermatitis and allergies.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

Armengot-Carbo M., Hernández-Martín Á., and Torrelo A. 2015. The role of filaggrin in the skin barrier and disease development. Actas Dermo-Sifiliogr. (Engl. Ed.), 106(2): 86–95.
Castagnoli R., Lougaris V., Giardino G., Volpi S., Leonardi L., La Torre F., Federici S., Corrente S., Cinicola B.L., Soresina A., Cancrini C., Marseglia G.L., and Cardinale F. 2021. Inborn errors of immunity with atopic phenotypes: A practical guide for allergists. World Allergy Organ. J. 14(2): 100513.
Čepelak I., Dodig S., and Pavić I. 2019. Filaggrin and atopic march. Biochem. Med. 29(2): 214–227.
Cheirif-Wolosky O., Elizalde-Jiménez I.G., and García-Romero M.T. 2022. Systemic treatment for severe atopic dermatitis in children: A case series. Bol. Méd. Hosp. Infant. México, 79(5): 8665.
Cubero J.L., Isidoro-García M., Segura N., Benito Pescador D., Sanz C., Lorente F., Dávila I., and Colás C. 2016. Filaggrin gene mutations and new SNPs in asthmatic patients: A cross-sectional study in a Spanish population. Allergy Asthma Clin. Immunol. 12(1): 31.
Drislane C. and Irvine A.D. 2020. The role of filaggrin in atopic dermatitis and allergic disease. Ann. Allergy Asthma Immunol. 124(1): 36–43.
Gan, E.Y., Cai, S.C.S., and Tang, M.B.Y. 2014. Filaggrin and skin infections. In Filaggrin. Edited by J.P. Thyssen, and H.I. Maibach. Springer Berlin Heidelberg. pp. 279–291.
Kim J., Kim B.E., Ahn K., and Leung D.Y.M. 2019. Interactions between atopic dermatitis and Staphylococcus aureus infection: Clinical implications. Allergy Asthma Immunol. Res. 11(5): 593.
Lee J.H., Yun S.-J., Lee J.-B., and Lee S.-C. 2020. Therapeutic efficacy and safety of methotrexate in moderate-to-severe atopic dermatitis: a retrospective study of Korean patients at tertiary referral hospital. Ann. Dermatol. 32(5): 402.
Margolis D.J., Apter A.J., Gupta J., Hoffstad O., Papadopoulos M., Campbell L.E., Sandilands A., McLean W.H.I., Rebbeck T.R., and Mitra N. 2012. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J. Allergy Clin. Immunol. 130(4): 912–917.
Margolis D.J., Mitra N., Gochnauer H., Wubbenhorst B., D’Andrea K., Kraya A., Hoffstad O., Gupta J., Kim B., Yan A., Fuxench Z.C., and Nathanson K.L. 2018. Uncommon filaggrin variants are associated with persistent atopic dermatitis in African Americans. J. Investig. Dermatol. 138(7): 1501–1506.
McAleer M.A. and Irvine A.D. 2013. The multifunctional role of filaggrin in allergic skin disease. J. Allergy Clin. Immunol. 131(2): 280–291.
Miajlovic H., Fallon P.G., Irvine A.D., and Foster T.J. 2010. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J. Allergy Clin. Immunol. 126(6): 1184–1190.e3.
Osawa R., Akiyama M., and Shimizu H. 2011. Filaggrin gene defects and the risk of developing allergic disorders. Allergol. Int. 60(1): 1–9.
Palmer C.N.A., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., Goudie D.R., Sandilands A., Campbell L.E., Smith F.J.D., O’Regan G.M., Watson R.M., Cecil J.E., Bale S.J., Compton J.G., DiGiovanna J.J., Fleckman P., Lewis-Jones S., Arseculeratne G., Sergeant A., Munro C.S., Houate B.L., McElreavey K., Halkjaer L.B., Bisgaard H., Mukhopadhyay S., and McLean W. H. I. 2006. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38(4): 441–446.
Pichard D.C., Freeman A.F., and Cowen E.W. 2015. Primary immunodeficiency update. J. Am. Acad. Dermatol. 73(3): 355–364.
Sokol K. and Milner J.D. 2018. The overlap between allergy and immunodeficiency. Curr. Opin. Pediatr. 30(6): 848–854.
Wang V., Boguniewicz J., Boguniewicz M., and Ong P.Y. 2021. The infectious complications of atopic dermatitis. Ann. Allergy Asthma Immunol. 126(1): 3–12.
Winge M.C.G., Bilcha K.D., Liedén A., Shibeshi D., Sandilands A., Wahlgren C.-F., McLean W.H.I., Nordenskjöld M., and Bradley M. 2011. Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. Br. J. Dermatol. 165(5): 1074–1080.
Yang G., Seok J. K., Kang H. C., Cho Y.-Y., Lee H.S., and Lee J.Y. 2020. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int. J. Mol. Sci. 21(8): 2867.

Information & Authors

Information

Published In

cover image LymphoSign Journal
LymphoSign Journal
Volume 11Number 1March 2024
Pages: 19 - 25

History

Received: 26 January 2024
Accepted: 21 February 2024
Accepted manuscript online: 12 March 2024
Version of record online: 5 April 2024

Authors

Affiliations

Azhar Al Shaqaq
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON
Lucy Dong Xuan Li
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON
Daniele Merico
The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON
Vevo Therapeutics, San Francisco, CA
Julia E. M. Upton [email protected]
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON

Metrics & Citations

Metrics

Other Metrics

Citations

Cite As

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

There are no citations for this item

View Options

Get Access

View options

PDF

View PDF

Full Text

View Full Text

Media

Media

Other

Tables

Share Options

Share

Share the article link

Share on social media